Cargando…

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition

PURPOSE: Hypoxia is a common characteristic of many tumor microenvironments, and it has been shown to promote suppression of antitumor immunity. Despite strong biological rationale, longitudinal correlation of hypoxia and response to immunotherapy has not been investigated. EXPERIMENTAL DESIGN: In t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reeves, Kirsten M., Song, Patrick N., Angermeier, Allyson, Manna, Deborah Della, Li, Yufeng, Wang, Jianbo, Yang, Eddy S., Sorace, Anna G., Larimer, Benjamin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Precision Medicine and Imaging
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776604/ https://www.ncbi.nlm.nih.gov/pubmed/34615724 http://dx.doi.org/10.1158/1078-0432.CCR-21-2394

Ejemplares similares

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Circulating metabolites associated with tumor hypoxia and early response to treatment in bevacizumab-refractory glioblastoma after combined bevacizumab and evofosfamide
por: Lodi, Alessia, et al.
Publicado: (2022)

(18)F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model
por: Grkovski, Milan, et al.
Publicado: (2018)

Phase 2 trial of hypoxia activated evofosfamide (TH302) for treatment of recurrent bevacizumab-refractory glioblastoma
por: Brenner, Andrew J., et al.
Publicado: (2021)

Elimination of tumor hypoxia by eribulin demonstrated by (18)F-FMISO hypoxia imaging in human tumor xenograft models
por: Zhao, Songji, et al.
Publicado: (2019)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

74325 Vast sex-specific differences in transcriptional landscapes of pancreatic neuroendocrine tumors
por: Ivanov, Nikolay A., et al.
Publicado: (2021)

81030 Utilizing a synergistic drug combination to target relapsed/refractory FLT3 mutant AML
por: Jones, LaQuita, et al.
Publicado: (2021)

FMISO accumulation in tumor is dependent on glutathione conjugation capacity in addition to hypoxic state
por: Masaki, Yukiko, et al.
Publicado: (2017)

The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
por: Lee, Jessica K., et al.
Publicado: (2022)

Monitoring Tumor Hypoxia Using (18)F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy
por: Tong, Xiao, et al.
Publicado: (2016)

CTLA4-Mediated Immunosuppression in Glioblastoma is Associated with the Infiltration of Macrophages in the Tumor Microenvironment
por: Guan, Xiudong, et al.
Publicado: (2021)

Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma
por: Burgener, Justin M., et al.
Publicado: (2021)

Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors
por: Nehmeh, Sadek A., et al.
Publicado: (2021)

A Combination of Radiation and the Hypoxia-Activated Prodrug Evofosfamide (TH-302) is Efficacious against a Human Orthotopic Pancreatic Tumor Model()()
por: Hajj, Carla, et al.
Publicado: (2017)

Usefulness of FMISO—PET for Glioma Analysis
por: Kobayashi, Hiroyuki, et al.
Publicado: (2013)

Gene-Expression Profiling of Mucinous Ovarian Tumors and Comparison with Upper and Lower Gastrointestinal Tumors Identifies Markers Associated with Adverse Outcomes
por: Meagher, Nicola S., et al.
Publicado: (2022)

CTLA-4 promotes lymphoma progression through tumor stem cell enrichment and immunosuppression
por: Chen, Yan, et al.
Publicado: (2021)

Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo
por: Huang, Yan, et al.
Publicado: (2018)

Quantitative MRI to Characterize Hypoxic Tumors in Comparison to FMISO PET/CT for Radiotherapy in Oropharynx Cancers
por: Gouel, Pierrick, et al.
Publicado: (2023)

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET
por: Huang, Shiliang, et al.
Publicado: (2021)

DNA-Methylome–Based Tumor Hypoxia Classifier Identifies HPV-Negative Head and Neck Cancer Patients at Risk for Locoregional Recurrence after Primary Radiochemotherapy
por: Tawk, Bouchra, et al.
Publicado: (2023)

Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma
por: Madanat-Harjuoja, Laura M., et al.
Publicado: (2022)

HPV Sequencing Facilitates Ultrasensitive Detection of HPV Circulating Tumor DNA
por: Leung, Eric, et al.
Publicado: (2021)

VCAM-1–targeted MRI Improves Detection of the Tumor-brain Interface
por: Cheng, Vinton W.T., et al.
Publicado: (2022)

Hypoxia-Targeting Drug Evofosfamide (TH-302) Enhances Sunitinib Activity in Neuroblastoma Xenograft Models()
por: Kumar, Sushil, et al.
Publicado: (2018)

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
por: Wang, Victoria E., et al.
Publicado: (2017)

266 Decoding the role of polyamine metabolism on anti-tumor immunity in head and neck cancer
por: Harbison, Richard Alexander, et al.
Publicado: (2023)

Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture‐Based Assay of Circulating Tumor DNA
por: Lai, Andrea Z., et al.
Publicado: (2017)

Gallium-68–labeled Peptide PET Quantifies Tumor Exposure of PD-L1 Therapeutics
por: Mishra, Akhilesh, et al.
Publicado: (2023)

Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
por: Martin, John D., et al.
Publicado: (2022)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models
por: Liapis, Vasilios, et al.
Publicado: (2016)

Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
por: Liapis, Vasilios, et al.
Publicado: (2017)

Targeting Refractory Mantle Cell Lymphoma for Imaging and Therapy Using C-X-C Chemokine Receptor Type 4 Radioligands
por: Kwon, Daniel, et al.
Publicado: (2022)

Diagnostic Performance of a Tumor Marker Gene Test to Personalize Serum CA19–9 Reference Ranges
por: Dbouk, Mohamad, et al.
Publicado: (2023)

Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer
por: Pellini, Bruna, et al.
Publicado: (2023)

Clinical Benefit of Sorafenib Combined with Paclitaxel and Carboplatin to a Patient with Metastatic Chemotherapy‐Refractory Testicular Tumors
por: Lian, Bijun, et al.
Publicado: (2019)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

Evofosfamide for the treatment of human papillomavirus-negative head and neck squamous cell carcinoma
por: Jamieson, Stephen M.F., et al.
Publicado: (2023)

291 High Potency STING Agonists Induce Adaptive Immunity-Dependent Curative Responses in an Immune Checkpoint Blockade-Refractory Glioblastoma Model
por: Lea, Spencer, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dlv0v9jds16ile6vhhg1fma685